Menu
remicade

REMICADE

60 252 руб.

Артикул: 31855.

60 252 руб.

Выбрать количество
Выбрать дозировку
Очистить
Стоимость
Сравнить

ПОКАЗАНИЯ К ПРИМЕНЕНИЮ

— Adult :- Crohn’s disease: Treatment of moderate to severe active Crohn’s disease in patients who have not responded despite of a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant. Treatment of fistulising Crohn’s disease in patients who have not responded despite of a full and adequate course of therapy with conventional treatment. — Paediatric Crohn’s disease: Remicade is indicated for: Treatment of severe active crohn’s disease in paediatric patients aged 6 to 17 years who have not responded to conventional therapy including a corticosteroid an immunomodulator and primary nutrition therapy or who are intolerant to or have contraindications for such therapies. Remicade has been studied only in combination with conventional immunosuppressive therapy — Ankylosing spondylitis: Remicade is indicated for: treatment of ankylosing spondylitis in patients who have severe axial symptoms elevated serological markers of inflammatory activity and who have responded inadequately to conventional therapy. — Psoriatic arthritis : Remicade is indicated for : Treatment of active and progressive psoriatic arthritis in adults when the response to previous DMARD therapy has been inadequate. Remicade should be administered : either in combination with methotrexate or alone in patients who show intolerance to methotrexate or for whom methotrexate is contraindicated. — Remicade has been shown to improve physical function in patients with psoriatic arthritis and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease. — Rheumatoid arthritis: Remicade in combination with methotrexate is indicated for the reduction of signs and symptoms as well as the improvement in physical function in: Patients with active disease when the response to disease-modifying drugs including methotrexate has been inadequate. Patients with severe active and progressive disease not previously treated with methotrexate or other DMARDs. In this these patient populations a reduction in the rate of the progression of joint damage as measured by x-ray has been demonstrated — Psoriasis: Remicade is indicated for: Treatment of moderate to severe plaque psoriasis in adults who failed to respond to or who have a contraindication to or are intolerant to other systemic therapy including cyclosporine methotrexate or PUVA. — Ulcerative colitis: Remicade is indicated for: Treatment of moderately to severely active ulcerative colitis in patients who have had an inadequate response to convential therapy including corticosteroids and 6-MP or AZA or who are intolerant to or have medical contraindications for such therapies.- Paediatric ulcerative colitis: Remicade is indicated for treatment of severely active ulcerative colitis, in paediatric patients aged 6 to 17 years, who have had an inadequate response to conventional therapy including corticosteroids and 6 MP or AZA, or who are intolerant to or have medical contraindications for such therapies

  • Действующее вещество : INFLIXIMAB
  • Производитель : JANSSEN BIOLOGICS B.V, THE NETHERLAND
  • Форма упаковки : VIAL 20 ML GLASS TYPE I
  • Срок годности : 36 мес.
  • Таможня : Без ограничений
  • Класс доставки : Авиапочта, до 5 дней
  • Информация о препарате от Минздрава Израиля : http://www.old.health.gov.il/units/pharmacy/trufot/PerutTrufa.asp?Reg_Number=137 18 29865 05&safa=e
  • По рецепту : Да

ПРЕПАРАТЫ С ТЕМ ЖЕ ДЕЙСТВУЮЩИМ ВЕЩЕСТВОМ

Описание товара

В Израиле В России
Ремикейд

Ревматоидный артрит (при неэффективности проведенной ранее терапии, в т.ч. метотрексатом). Болезнь Крона (тяжелое течение, в т.ч. с образованием свищей; при неэффективности стандартной терапии, включая ГКС и/или иммунодепрессанты).

Ремикейд

Additional Information

Количество в упаковке

1 X VIAL